J&J Drug Pricing Deal With Trump Administration Cuts Prices and Expands U.S. Manufacturing
Johnson & Johnson inks a voluntary deal with the Trump Administration to lower drug prices, align U.S. pricing with Europe, and boost domestic manufacturing.
Latest right now for #pharma
Zepbound Price Cut: $499/Month Self-Pay Vials Amid Access Push
Eli Lilly trims Zepbound vial prices to $499/month for self-pay patients, signaling broader obesity drug affordability amid industry and political pushes.
Pfizer's Monthly GLP-1 Obesity Injection Shows Competitive Promise
Pfizer's PF-08653944 shows promising monthly dosing with notable weight loss in the VESPER-3 trial and a competitive edge over weekly injections.
Pfizer Wins $10B Metsera Acquisition Expands Obesity Treatment Pipeline
Pfizer secures a $10B deal to acquire Metsera, boosting obesity therapies and signaling strategic growth in biotech.
Historic US-UK Pharma Tariff Elimination Boosts Life Sciences
The US and UK strike zero-tariff pharma exports deal, boosting patient access and UK life sciences investment.
Atorvastatin Recall Triggers Patient Concern: FDA Oversight and Global Supply Chain Risks
Massive recall of atorvastatin due to dissolution failures raises FDA oversight and global supply chain concerns.
Trump's Pharma Tariffs: Impact on Drugs, Prices, and Patients
Explores Trump's 100% tariffs on foreign drugs, potential price spikes, supply concerns, and impact on patients needing essential medications.
